5 Key Takeaways

• 1

  Myopia is now recognized as a progressive disease with significant risks for ocular pathology, including retinal detachment and glaucoma.

• 2

  Public health organizations advocate for myopia management to delay onset and slow progression, emphasizing its importance in standard eye care.

• 3

  Economic modeling indicates that myopia incurs substantial productivity losses globally, affecting both individuals and society.

• 4

  Low-dose atropine is a versatile pharmacologic therapy for myopia control, particularly effective in younger children and those with rapid progression.

• 5

  Axial length measurements and the AL/CR ratio are critical for risk assessment in myopia management, aiding in early intervention decisions.